Assembly Biosciences (ASMB) closed at $20.57 on October 28, 2026, up 1.3% from the previous close, on volume of 138,562 shares (30-day average 295,289).
Data as of October 28, 2026.
Healthcare stocks with strong revenue growth and attractive valuations
Seeking Alpha News (Tue, 27-Oct 7:10 AM ET)
Globe Newswire (Mon, 5-Oct 10:00 AM ET)
Globe Newswire (Thu, 10-Sep 4:15 PM ET)
Globe Newswire (Tue, 8-Sep 4:00 PM ET)
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
Globe Newswire (Thu, 13-Aug 4:00 PM ET)
Market Chameleon (Fri, 20-Mar 5:59 AM ET)
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Assembly Biosciences trades on the NASDAQ stock market under the symbol ASMB.
As of October 28, 2026, ASMB stock price climbed to $20.57 with 138,562 million shares trading.
ASMB has a beta of 1.01, meaning it tends to be more sensitive to market movements. ASMB has a correlation of 0.05 to the broad based SPY ETF.
ASMB has a market cap of $418.82 million. This is considered a Small Cap stock.
Last quarter Assembly Biosciences reported $13 million in Revenue and -$.20 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.36.
In the last 3 years, ASMB traded as high as $39.71 and as low as $7.69.
The top ETF exchange traded funds that ASMB belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
ASMB has underperformed the market in the last year with a return of -31.0%, while the SPY ETF gained +13.8%. In the last 3 month period, ASMB fell short of the market, returning -20.6%, while SPY returned +4.8%. However, in the most recent 2 weeks ASMB has outperformed the stock market by returning +1.1%, while SPY returned -0.7%.
ASMB support price is $19.56 and resistance is $21.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASMB shares will trade within this expected range on the day.
